Eumycetoma: pathogenesis, current treatments, and the search for new drugs
Abstract Eumycetoma is a neglected tropical disease which can be caused by 69 different fungal species. In 2024, eumycetoma was listed as a high priority fungal infection on the fungal priority list of the World Health Organization. Eumycetoma is characterized by chronic subcutaneous swelling, the f...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-08-01
|
| Series: | Applied Microbiology and Biotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00253-025-13580-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226471565950976 |
|---|---|
| author | Dounia El Yachioui Tim Baltussen Wendy W. J. van de Sande |
| author_facet | Dounia El Yachioui Tim Baltussen Wendy W. J. van de Sande |
| author_sort | Dounia El Yachioui |
| collection | DOAJ |
| description | Abstract Eumycetoma is a neglected tropical disease which can be caused by 69 different fungal species. In 2024, eumycetoma was listed as a high priority fungal infection on the fungal priority list of the World Health Organization. Eumycetoma is characterized by chronic subcutaneous swelling, the formation of grains, and progressive tissue destruction. If left untreated, it can lead to severe complications such as bone destruction and permanent disability. Current antifungal treatments, such as itraconazole and terbinafine, are lengthy and often ineffective without surgical intervention. The search for novel treatments is challenging due to limited interest and return of investment. Drug repurposing has emerged as a promising strategy for discovering new effective therapies against eumycetoma. Additionally, the MycetOS initiative focuses on developing novel antifungal compounds that are tested in vitro and in vivo. Key points Pathogenesis involves the formation of grains to protect the fungus New treatments are needed for eumycetoma to reduce recurrence and amputation rates Drug repurposing and MycetOS are key strategies for developing new treatments |
| format | Article |
| id | doaj-art-0269d74d4ff044bb9fb4f90b3b7419db |
| institution | Kabale University |
| issn | 1432-0614 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Springer |
| record_format | Article |
| series | Applied Microbiology and Biotechnology |
| spelling | doaj-art-0269d74d4ff044bb9fb4f90b3b7419db2025-08-24T11:13:33ZengSpringerApplied Microbiology and Biotechnology1432-06142025-08-01109111010.1007/s00253-025-13580-5Eumycetoma: pathogenesis, current treatments, and the search for new drugsDounia El Yachioui0Tim Baltussen1Wendy W. J. van de Sande2Department of Medical Microbiology and Infectious Diseases, Erasmus MCDepartment of Medical Microbiology and Infectious Diseases, Erasmus MCDepartment of Medical Microbiology and Infectious Diseases, Erasmus MCAbstract Eumycetoma is a neglected tropical disease which can be caused by 69 different fungal species. In 2024, eumycetoma was listed as a high priority fungal infection on the fungal priority list of the World Health Organization. Eumycetoma is characterized by chronic subcutaneous swelling, the formation of grains, and progressive tissue destruction. If left untreated, it can lead to severe complications such as bone destruction and permanent disability. Current antifungal treatments, such as itraconazole and terbinafine, are lengthy and often ineffective without surgical intervention. The search for novel treatments is challenging due to limited interest and return of investment. Drug repurposing has emerged as a promising strategy for discovering new effective therapies against eumycetoma. Additionally, the MycetOS initiative focuses on developing novel antifungal compounds that are tested in vitro and in vivo. Key points Pathogenesis involves the formation of grains to protect the fungus New treatments are needed for eumycetoma to reduce recurrence and amputation rates Drug repurposing and MycetOS are key strategies for developing new treatmentshttps://doi.org/10.1007/s00253-025-13580-5MycetomaDrug discoveryFungal infectious diseaseMycetOS |
| spellingShingle | Dounia El Yachioui Tim Baltussen Wendy W. J. van de Sande Eumycetoma: pathogenesis, current treatments, and the search for new drugs Applied Microbiology and Biotechnology Mycetoma Drug discovery Fungal infectious disease MycetOS |
| title | Eumycetoma: pathogenesis, current treatments, and the search for new drugs |
| title_full | Eumycetoma: pathogenesis, current treatments, and the search for new drugs |
| title_fullStr | Eumycetoma: pathogenesis, current treatments, and the search for new drugs |
| title_full_unstemmed | Eumycetoma: pathogenesis, current treatments, and the search for new drugs |
| title_short | Eumycetoma: pathogenesis, current treatments, and the search for new drugs |
| title_sort | eumycetoma pathogenesis current treatments and the search for new drugs |
| topic | Mycetoma Drug discovery Fungal infectious disease MycetOS |
| url | https://doi.org/10.1007/s00253-025-13580-5 |
| work_keys_str_mv | AT douniaelyachioui eumycetomapathogenesiscurrenttreatmentsandthesearchfornewdrugs AT timbaltussen eumycetomapathogenesiscurrenttreatmentsandthesearchfornewdrugs AT wendywjvandesande eumycetomapathogenesiscurrenttreatmentsandthesearchfornewdrugs |